Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04980222 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
A Phase 2 study of Lymphoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 18
- Study locations
NCT04980222: Active Phase 2 study of Lymphoma, sponsored by Hoffmann-La Roche.
NCT04980222 is a Phase 2 study of Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 46 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 18 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04980222, a Phase 2 study of Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 18
- Study locations
Study Summary
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in individuals with circulating tumor DNA (ctDNA) high-risk diffuse large B-cell lymphoma (DLBCL), as the first line of treatment.
Conditions Studied
Interventions
- DRUG Glofitamab
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Prednisone
- DRUG Tocilizumab
Study Locations (18)
Other
- Aarhus Universitetshospital Skejby - Aarhus N
- Hopital Henri Mondor - Créteil
- Centre Henri Becquerel - Rouen
- Universitair Medisch Centrum Groningen - Groningen
- Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii - Gdansk
- Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku - Wroclaw
- Hospital Clinic i Provincial de Barcelona - Barcelona
- Hospital General Universitario Gregorio Marañon - Madrid
- Hospital Univ. 12 de Octubre; Servicio de Hematologia - Madrid
- Hospital Clinico Universitario de Salamanca - Salamanca
California
- City of Hope Comprehensive Cancer Center - Duarte
- Stanford Cancer Center - Stanford
New York
- Memorial Sloan Kettering Cancer Center at Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
Iowa
- University of Iowa - Iowa City
Missouri
- Washington University; Wash Uni. Sch. Of Med - St Louis
New Jersey
- Memorial Sloan Kettering Bergen - Montvale
Texas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What the registry record for NCT04980222 still lists
NCT04980222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Glofitamab is the first listed.
NCT04980222 lists 18 locations in 7 states (Other, California, New York).
Frequently Asked Questions
What is clinical trial NCT04980222 about?
NCT04980222 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma". This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in individuals with circulating tumor DNA (ctDNA) high-risk diffus...
What is the current status of trial NCT04980222?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2022-03-22. Estimated completion is 2026-09-30.
What conditions does trial NCT04980222 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT04980222?
The interventions under investigation include: Glofitamab (DRUG), Doxorubicin (DRUG), Vincristine (DRUG), Prednisone (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT04980222?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04980222 being conducted?
This trial has 18 study locations across California, Iowa, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04980222's enrollment target sits among peer trials
46 162nd of 299 higher than 138 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI